31 results
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
9 Nov 23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
8:07am
in a poster session at the upcoming 65th Annual Meeting of the American Society of Hematology (ASH), taking place December 9-12, 2023 in San Diego, CA
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
31 Oct 23
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
4:25pm
presentations at the annual meetings of both the Clinical Immunology Society (CIS) and European Hematology Association (EHA).
About WHIM Syndrome
WHIM syndrome
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
5 Sep 23
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
5:00pm
in oral presentations at the annual meetings of both the Clinical Immunology Society (CIS) and European Hematology Association (EHA).
About
8-K
EX-99.1
XFOR
X4 Pharmaceuticals Inc
10 Aug 23
Provides Corporate Updates, and Reports Emerging Data from
6:41am
at a company webinar in May 2023 and at the Annual Meetings of both the Clinical Immunology Society (CIS) and the European Hematology Association (EHA
8-K
EX-99.3
9jhu53w c3cvyyyq6tkj
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
8-K
EX-99.2
fx3ucgyremqe2 6o5ga7
16 May 23
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
4:24pm
8-K
EX-99.1
iyps0w3yt
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
9:05am
8-K
EX-99.1
jq5o93fg3xzcr9w3up96
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
6:42am
8-K
EX-99.1
btogduwtjovnv1q47
17 Mar 22
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
8:23am
8-K
EX-99.1
a4umb
4 Nov 21
Results of Operations and Financial Condition
9:01am